-

11:08:35 AM

BPMC Stock News

BPMC - Blueprint Medicines Corp

06/05/23 5:00 PM

Nasdaq : BPMC

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation, today announced that, effective June 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 7,593 shares of its common stock and an aggregate of 3,796 restricted stock units to six new employees...

RHEA-AI

very positive

06/03/23 9:00 AM

Nasdaq : BPMC

Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting

Blueprint Medicines Corporation today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society...

RHEA-AI

neutral

05/23/23 10:00 AM

Nasdaq : BPMC

NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis

Blueprint Medicines Corporation today announced that NEJM Evidence, a journal from The New England Journal of Medicine Group, has published detailed results from the PIONEER trial of AYVAKIT ® in patients with indolent systemic mastocytosis.

RHEA-AI

neutral

05/22/23 4:04 PM

Nasdaq : BPMC

fda approval

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

Blueprint Medicines Corporation today announced that the U.S. All U.S. patients with ISM now have access to the first and only approved medicine designed to treat...

RHEA-AI

neutral

05/04/23 5:01 PM

Nasdaq : BPMC

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation today announced that, effective May 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 18,300 shares of its common stock and an aggregate of 9,146 restricted stock units to eleven new...

RHEA-AI

very positive

05/04/23 7:00 AM

Nasdaq : BPMC

earnings

Blueprint Medicines Reports First Quarter 2023 Results

. CAMBRIDGE, Mass., May 4, 2023/...

RHEA-AI

neutral

04/26/23 10:00 AM

Nasdaq : BPMC

conferencesclinical trial

Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting

Blueprint Medicines Corporation today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology Annual Meeting, June 2 to 6. The presentations showcase Blueprint Medicines' next wave of therapeutic candidates in its robust clinical pipeline, and...

RHEA-AI

neutral

04/20/23 4:01 PM

Nasdaq : BPMC

conferencesearnings

Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

Blueprint Medicines Corporation today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023 to report its first quarter financial results and provide a corporate update. A webcast of the call will also be available under "Events and Presentations" in the Investors& Media section of the Blueprint Medicines...

RHEA-AI

neutral

04/11/23 8:00 AM

Nasdaq : BPMC

conferences

Blueprint Medicines to Present at Upcoming Investor Conferences

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced its participation in the following upcoming investor conferences:22 nd Annual Needham Healthcare Conference, held virtually, on Tuesday, April 18, 2023 at 2:15 p.m. ET. Stifel 2023

RHEA-AI

neutral

04/05/23 4:01 PM

Nasdaq : BPMC

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective April 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 5,933 shares of its common...

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

BPMC Data

IndustryPharmaceutical Preparation Manufacturing
Websiteblueprintmedicines.com
CeoJeffrey Albers
Security nameBlueprint Medicines Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees495
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address45 Sidney St
StateMassachusetts
CityCambridge
Zip02139-4133
CountryUS
Phone16173747580

About Blueprint Medicines Corp

blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development